CTKB vs. TXG, TRNS, SENS, LAB, ALNT, EYPT, AEHR, QTRX, QSI, and NAUT
Should you be buying Cytek Biosciences stock or one of its competitors? The main competitors of Cytek Biosciences include 10x Genomics (TXG), Transcat (TRNS), Senseonics (SENS), Standard BioTools (LAB), Allient (ALNT), EyePoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Quanterix (QTRX), Quantum-Si (QSI), and Nautilus Biotechnology (NAUT). These companies are all part of the "measuring and control equipment" industry.
Cytek Biosciences vs.
Cytek Biosciences (NASDAQ:CTKB) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, community ranking, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.
In the previous week, 10x Genomics had 30 more articles in the media than Cytek Biosciences. MarketBeat recorded 32 mentions for 10x Genomics and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.63 beat 10x Genomics' score of 0.15 indicating that Cytek Biosciences is being referred to more favorably in the media.
Cytek Biosciences has a net margin of -5.05% compared to 10x Genomics' net margin of -29.90%. Cytek Biosciences' return on equity of -2.58% beat 10x Genomics' return on equity.
10x Genomics received 40 more outperform votes than Cytek Biosciences when rated by MarketBeat users. Likewise, 51.72% of users gave 10x Genomics an outperform vote while only 44.44% of users gave Cytek Biosciences an outperform vote.
Cytek Biosciences has higher earnings, but lower revenue than 10x Genomics. Cytek Biosciences is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks.
Cytek Biosciences presently has a consensus price target of $6.50, suggesting a potential upside of 27.08%. 10x Genomics has a consensus price target of $20.57, suggesting a potential upside of 88.73%. Given 10x Genomics' stronger consensus rating and higher possible upside, analysts clearly believe 10x Genomics is more favorable than Cytek Biosciences.
69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 9.6% of Cytek Biosciences shares are owned by company insiders. Comparatively, 10.0% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Cytek Biosciences has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.
Summary
10x Genomics beats Cytek Biosciences on 11 of the 18 factors compared between the two stocks.
Get Cytek Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytek Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CTKB) was last updated on 2/21/2025 by MarketBeat.com Staff
